GLP-1 Was Just the Beginning. The First Triple-Hormone Obesity Drug Now Has Phase 3 Data
For the last several years, one acronym has dominated the conversation around obesity treatment: GLP-1. First came drugs that targeted the…
Insulin Just Went From 365 Injections a Year to 52. Now Two Once-Weekly Options Are Approved.
For more than a century, insulin has steadily evolved. We’ve developed faster insulins for meals, longer-acting insulins for basal…
GLP-1s and the Lungs: Semaglutide Linked to 40% Fewer Asthma Attacks
New real-world data from the ERS Congress 2026 (Barcelona) Semaglutide was associated with up to a 40% reduction in asthma attacks, according…
One of Cardiology’s Most Promising Drug Targets Just Failed Its First Big Test — And the Lp(a) Race Is Now Wide Open
Earlier this year, the ACC and AHA made a major change to cholesterol screening: the 2026 guideline says every adult should have their…
The First Continuous Ketone Sensor Just Got Cleared – Abbott Closes Diabetes Monitoring’s Oldest Blind Spot
For four decades, ketone testing meant a urine strip or a fingerstick giving a single snapshot, no trend, and only if the patient remembered…